glp-1 and naion Ophthalmic Complications Observed After Use of Agonists GLP-1 receptor agonist use linked

Concerns around misuse and market practices The commercialization of obesity drugs has also raised several concerns: Increasing availability without proper prescriptions Off-label use among individuals without clinical indications Marketing of these drugs as quick weight-loss solutions Entry of inadequately tested products positioned as supplements Such practices pose risks to patient safety and may undermine confidence in these therapies if adverse events increase

I was diagnosed the very next day

Hyper-Activation of Endogenous GLP-1 System to Gram-Negative Sepsis Is Associated with Early Innate Immune Response and Modulated by Diabetes

University of Colorado Anschutz Medical Campus